Patent cliffs and the generics counterattack

Payers and Pharmacy Benefit Managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx sit between manufacturers and patients in the US, negotiating rebates and deciding which drugs get preferred placement on formularies (the list of covered drugs).

Regulators: the FDA (US Food and Drug Administration) approves generics and biosimilars; the EMA (European Medicines Agency) does the equivalent in the EU. Antitrust bodies like the FTC (Federal Trade Commission) and the European Commission police anti-competitive patent behavior.

How originators defend the cliff: the patent thicket

AbbVie didn't rely on one patent for Humira. It built a patent thicket: a dense web of over 100 patents covering the drug's formulation, manufacturing process, dosing regimens, and delivery device, filed at different times to push expiration dates further out.

The core Humira patent expired in 2016. Actual biosimilar competition didn't arrive in the US until 2023, seven years later. In Europe, where patent thickets are harder to sustain and the EMA approved Humira biosimilars back in 2018, competition arrived far sooner and prices fell faster (estimate: some European markets saw price drops of 80%+ within two years, per European Commission biosimilars reporting).

This gap illustrates a core power dynamic: originators use IP law and regulatory complexity as competitive weapons, and the effectiveness of that weapon differs by jurisdiction.

Other originator defense tactics:

• Pay-for-delay settlements: originators pay generic challengers to postpone launch. Scrutinized heavily by the FTC as potentially anticolluutive.
• Product hopping: shifting patients to a slightly reformulated version (say, a new dose or delivery device) before the original goes generic, resetting exclusivity.
• Authorized generics: the originator launches its own generic version through a subsidiary, capturing some of the low-price volume itself rather than ceding it entirely.
• Rebate strategies with PBMs: AbbVie reportedly offered steep rebates to PBMs to keep Humira preferred on formularies even after biosimilars launched at lower list prices, a tactic that drew Congressional scrutiny in 2023-2024.

Why Humira held share even after the cliff

This is the counterintuitive part students often miss: even after nine biosimilars launched in the US in 2023, AbbVie retained an estimated majority of Humira's US market sharemarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.Voir la définition complète → through 2024 (estimate, based on AbbVie earnings commentary).

Why? Because in the US, formulary placement decided by PBMs matters more than list price. Biosimilar makers had to negotiate their way onto formularies, competing on rebates to PBMs rather than just on price to patients. AbbVie's existing rebate relationships gave it a defensive moatmoatA lasting edge over competitors: a resource, capability or position they cannot easily replicate, letting a firm earn above-average returns over time.Voir la définition complète → that had nothing to do with patents.

This is a critical lesson in pharma power dynamics: patent law determines when competition is legally allowed to start; distribution and payer relationships determine how much that competition actually bites.

The challenger's playbook

Biosimilar and generic makers compete on:

• Speed to file: being first to submit an Abbreviated New Drug Application (ANDA, the US generic approval pathway) or a biosimilar application can earn exclusivity periods of its own (180 days of market exclusivity for the first generic challenger under the Hatch-Waxman Act).
• Manufacturing scale: margins on generics are thin, often single digits, so volume and low-cost manufacturing (frequently based in India or China) are decisive.
• Interchangeability status: in the US, a biosimilar designated "interchangeable" by the FDA can be substituted at the pharmacy without prescriber approval, a meaningfully stronger commercial position.

Companies like Sandoz (spun off from Novartis in 2023 specifically to focus on generics and biosimilars) and Viatris (formed from the Mylan-Pfizer Upjohn merger) exist because this is a distinct enough business, low margin, high volume, regulatory-arbitrage-driven, that it benefits from separation from high-margin innovator pharma.

Value distribution across the chain

Who actually captures the margin as a drug moves through its lifecycle?

Pre-LOE (on-patent): originator captures the overwhelming majority of value. List prices are high; PBM rebates carve out a meaningful slice (often 30-50% of list price in the US, estimate) but the manufacturer still nets high margins.

Post-LOE, generics (small molecule): price collapses fast, often 80-90% within 1-2 years in the US. Margin shifts to whichever generic manufacturer achieves lowest-cost production at scale. Distributors (McKesson, Cencora, Cardinal Health) take a smaller but stable cut regardless of which manufacturer wins.

Post-LOE, biosimilars: price erosion is slower and shallower (often 30-50% over several years, estimate), because manufacturing complexity limits the number of viable entrants and payer/PBM dynamics slow substitution. Margin stays split longer between originator and a handful of biosimilar makers.

Worked illustration: Assume Humira's US net price pre-LOE was roughly $80,000/year per patient (estimate, based on list price minus typical rebates). If a biosimilar enters at a 30% discount, that's roughly $56,000. If PBM formulary dynamics keep the originator's effective net price competitive through rebates, the originator can defend share even without matching the sticker discount, because payers care about net cost after rebate, not list price. This is why headline "biosimilar discount" percentages often overstate the actual competitive threat in year one.

Europe versus the US: a regulatory power contrast

Europe generally sees faster, deeper biosimilar erosion because:

• EMA approval pathways are more standardized and predictable
• National health systems, not fragmented PBMs, often mandate or strongly incentivize biosimilar switching
• Tendering systems in countries like Norway and Denmark let biosimilar makers win entire national contracts on price, creating rapid, visible share shifts

This is a useful comparison for understanding how the same molecule can face completely different power dynamics depending on payer structure.

🎬 [VIDEO: "How Drug Patents Work (And How Companies Extend Them)" - youtube.com - search for recent explainers from Marginal Revolution University or similar economics education channels covering pharma IP strategy]

For a regulatory primer, the FDA's biosimilars overview is a solid, free, authoritative reference.

Key Takeaways

• A patent cliff is a legal event; the actual revenue cliff depends on manufacturing complexity (small molecule vs. biologic), payer structure, and originator defensive tactics.
• Originators defend margin post-patent-expiry through patent thickets, product hopping, authorized generics, and PBM rebate strategies, not just litigation.
• Challengers compete on speed to file, manufacturing scale, and interchangeability status; margins are thin, so volume and cost position determine winners.
• The US and Europe show sharply different erosion curves for the same drug because of payer and regulatory structure, not just patent law, proving that distribution power can rival IP power.
• Headline biosimilar "discount" percentages often overstate real-world competitive impact; net price after rebates is what actually determines share shifts.